These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 39238035)

  • 1. Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial.
    Liao J; Wang Z; Zhang J; Tan H; Zhang Z; Zhang S; Hu S; Geng H; Zhan Z; Wei J; Li Z; Jia E
    Trials; 2024 Sep; 25(1):590. PubMed ID: 39238035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    McInnes IB; Anderson JK; Magrey M; Merola JF; Liu Y; Kishimoto M; Jeka S; Pacheco-Tena C; Wang X; Chen L; Zueger P; Liu J; Pangan AL; Behrens F
    N Engl J Med; 2021 Apr; 384(13):1227-1239. PubMed ID: 33789011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
    McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Pacheco-Tena C; Haaland D; Chen L; Duan Y; Zueger P; Liu J; Lippe R; Pangan AL; Behrens F
    RMD Open; 2021 Oct; 7(3):. PubMed ID: 34663636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V; Mease PJ; Soriano ER; Kishimoto M; Salvarani C; Saffore CD; Zueger P; McDearmon-Blondell E; Kato K; Gladman DD
    Rheumatol Ther; 2021 Dec; 8(4):1789-1808. PubMed ID: 34636026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
    Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
    Mease PJ; Lertratanakul A; Anderson JK; Papp K; Van den Bosch F; Tsuji S; Dokoupilova E; Keiserman M; Wang X; Zhong S; McCaskill RM; Zueger P; Pangan AL; Tillett W
    Ann Rheum Dis; 2021 Mar; 80(3):312-320. PubMed ID: 33272960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
    Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
    Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC.
    Coates LC; Garrood T; Gullick N; Helliwell P; Kent T; Marks J; Tillett W; Kaur-Papadakis D; Tahir H; van Haaren S; McInnes I
    Rheumatology (Oxford); 2022 Dec; 62(1):e1-e3. PubMed ID: 35799375
    [No Abstract]   [Full Text] [Related]  

  • 13. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
    Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J
    Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
    Fleischmann R; Swierkot J; Penn SK; Durez P; Bessette L; Bu X; Khan N; Li Y; Peterfy CG; Tanaka Y; Mysler E
    RMD Open; 2024 May; 10(2):. PubMed ID: 38806190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.
    McInnes IB; Ostor AJK; Mease PJ; Tillett W; Baraliakos X; de Vlam K; Bessette L; Lippe R; Maniccia A; Feng D; Gao T; Zueger P; Saffore C; Kato K; Song IH; Deodhar A
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35332058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
    Mease PJ; Ory P; Sharp JT; Ritchlin CT; Van den Bosch F; Wellborne F; Birbara C; Thomson GT; Perdok RJ; Medich J; Wong RL; Gladman DD
    Ann Rheum Dis; 2009 May; 68(5):702-9. PubMed ID: 18684743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
    Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
    Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
    Mease P; Setty A; Papp K; Van den Bosch F; Tsuji S; Keiserman M; Carter K; Li Y; McCaskill R; McDearmon-Blondell E; Wung P; Tillett W
    Clin Exp Rheumatol; 2023 Nov; 41(11):2286-2297. PubMed ID: 37404160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
    Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
    Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of upadacitinib in the treatment of psoriatic arthritis.
    Ross Y; Magrey M
    Immunotherapy; 2021 Dec; 13(18):1549-1554. PubMed ID: 34645316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.